Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
agenT-797 in relapsed/refractory multiple myeloma
NCT04754100Phase 1Completed
- Sponsor
- MiNK Therapeutics
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Allogeneic CAR-T, Lymphokine-Activated Killer Cells, Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of agenT-797 in multiple myeloma (MM), sponsored by MiNK Therapeutics. Primary endpoints: Number Of Participants With Treatment-related Adverse Events and Number Of Dose-limiting Toxicities. Started Mar 2021; status: completed.
02
Drugs
agenT-797
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04754100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754100.